361 related articles for article (PubMed ID: 22067401)
21. B-Raf Inhibition in the Clinic: Present and Future.
Fiskus W; Mitsiades N
Annu Rev Med; 2016; 67():29-43. PubMed ID: 26768236
[TBL] [Abstract][Full Text] [Related]
22. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
23. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Kopetz S; Desai J; Chan E; Hecht JR; O'Dwyer PJ; Maru D; Morris V; Janku F; Dasari A; Chung W; Issa JP; Gibbs P; James B; Powis G; Nolop KB; Bhattacharya S; Saltz L
J Clin Oncol; 2015 Dec; 33(34):4032-8. PubMed ID: 26460303
[TBL] [Abstract][Full Text] [Related]
24. Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy.
Cohen DN; Lawson SK; Shaver AC; Du L; Nguyen HP; He Q; Johnson DB; Lumbang WA; Moody BR; Prescott JL; Chandra PK; Boyd AS; Zwerner JP; Robbins JB; Tyring SK; Rady PL; Chappell JD; Shyr Y; Infante JR; Sosman JA
Clin Cancer Res; 2015 Jun; 21(11):2624-34. PubMed ID: 25724524
[TBL] [Abstract][Full Text] [Related]
25. (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Schneider TC; Kapiteijn E; van Wezel T; Smit JWA; van der Hoeven JJM; Morreau H
BMC Cancer; 2016 Jan; 16():31. PubMed ID: 26786320
[TBL] [Abstract][Full Text] [Related]
26. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
Smith KJ; Haley H; Hamza S; Skelton HG
Dermatol Surg; 2009 Nov; 35(11):1766-70. PubMed ID: 19660024
[TBL] [Abstract][Full Text] [Related]
27. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib-induced progression of breast cancer: a case report and review of the literature.
Novik AV; Protsenko SA; Baldueva IA; Ivantsov AO; Nekhaeva TL; Akhaeva ZY; Yanus GA; Iyevleva AG; Imyanitov EN
Target Oncol; 2016 Apr; 11(2):235-8. PubMed ID: 26264150
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus evaluation of vemurafenib-induced skin epithelial tumors: a case series.
Dika E; Patrizi A; Venturoli S; Fanti PA; Barbieri D; Strammiello R; Melotti B; La Placa M
Br J Dermatol; 2015 Feb; 172(2):540-2. PubMed ID: 25041062
[No Abstract] [Full Text] [Related]
31. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
32. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
33. Paradoxical oncogenesis: are all BRAF inhibitors equal?
Menzies AM; Kefford RF; Long GV
Pigment Cell Melanoma Res; 2013 Sep; 26(5):611-5. PubMed ID: 23795808
[TBL] [Abstract][Full Text] [Related]
34. Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab.
Picard A; Pedeutour F; Peyrade F; Saudes L; Duranton-Tanneur V; Chamorey E; Cardot-Leccia N; Sudaka A; Ettaiche M; Benchetrit M; Poissonnet G; Weinbreck N; Dadone B; Lacour JP; Passeron T; Montaudié H
JAMA Dermatol; 2017 Apr; 153(4):291-298. PubMed ID: 28259104
[TBL] [Abstract][Full Text] [Related]
35. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Hong DS; Reddy SB; Prieto VG; Wright JJ; Tannir NM; Cohen PR; Diwan AH; Evans HL; Kurzrock R
Arch Dermatol; 2008 Jun; 144(6):779-82. PubMed ID: 18559769
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
37. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
38. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM; Boehm JS; Kim SY; Thomas SR; Wardwell L; Johnson LA; Emery CM; Stransky N; Cogdill AP; Barretina J; Caponigro G; Hieronymus H; Murray RR; Salehi-Ashtiani K; Hill DE; Vidal M; Zhao JJ; Yang X; Alkan O; Kim S; Harris JL; Wilson CJ; Myer VE; Finan PM; Root DE; Roberts TM; Golub T; Flaherty KT; Dummer R; Weber BL; Sellers WR; Schlegel R; Wargo JA; Hahn WC; Garraway LA
Nature; 2010 Dec; 468(7326):968-72. PubMed ID: 21107320
[TBL] [Abstract][Full Text] [Related]
39. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
40. Vemurafenib Active in Iodine-Refractory Thyroid Cancer.
Cancer Discov; 2016 Oct; 6(10):OF4. PubMed ID: 27554612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
